iShares US Healthcare Providers

Clough Capital Partners L P Significantly Reduces Stake in UnitedHealth Group by 80.2%

Chevy Chase Trust Holdings LLC Cuts Holdings in UnitedHealth Group by 5.3%

Investment firm Clear Street Group acquires a new stake in UnitedHealth Group, purchasing shares worth approximately $294 million

Senator Markwayne Mullin discloses purchase of UnitedHealth Group stock

UnitedHealth Group to pay a quarterly dividend of $2.21 per share

Quest Diagnostics sees short interest drop in February and raises quarterly dividend

UnitedHealth Group begins restoring the Change Healthcare payment platform disrupted by a cyberattack.

Multiple Brokerages Lower Price Targets for UnitedHealth Group

Sirios Capital Management L P Increased Tenet Healthcare Corp Stock Holdings

Report shows UnitedHealth and other insurers are pulling back from some Medicare Advantage markets

UnitedHealth Group plans to save nearly $1 billion in 2026 through AI

Callodine Capital Management LP Reduces Holdings in CVS Health Corporation

Multiple Investment Firms Disclose Increased Stakes in UnitedHealth Group

UnitedHealth Group Appoints New CAO and Files Omnibus Shelf Registration

Prudential PLC Sells Shares of UnitedHealth Group

Archon Partners LLC Takes $6.91 Million Position in UnitedHealth Group

Dodge & Cox Purchases 755,076 Shares of UnitedHealth Group

Veeva Systems Acquires Ostro to Enhance AI-Driven Interactions

HCA Healthcare Inc. Releases 2025 Annual Report

Cigna Releases 2025 Annual Report, Introducing Multiple Improvement Measures and Reporting Major Investments and Business Sales

bioAffinity Tech

Firefly Neuroscience

Silvaco

eLong Power

T-REX 2X Long UPXI Daily Target ETF

Polaryx Therapeutics

TCW Strategic Income Fund, Inc.

Stak

iSpecimen

Oruka Therapeutics

VSEE

VSEEW

Oneview Healthcare Raises A$19m in Upsized Placement and Launches SPP to Fund AI and Growth

Tip Ranks

Viemed Healthcare

VSee Health

SPDR S&P Health

Health Care Select Sector SPDR

VG Health

Oneview Healthcare PLC Chess Depository Interests repr 1

BlackRock, Inc.

VSEE HEALTH INC C/WTS (TO PUR COM)

iShares Global Healthcare

Oneview Healthcare Raises A$19m in Upsized Placement and Launches SPP to Fund AI and Growth

On March 15th, CCTV's 315 Gala exposed the chaos in exosome medical aesthetics, pointing out that there are currently no exosome drugs approved for sale in China. The So-Young platform previously had the Qiaoluo Shi AR exosome project for sale, but it has now been removed. When reporters searched for "exosome" on the So-Young mini program and APP, they found that the related projects had disappeared

腾讯新闻 - 财经

So-Young

iShares US Medical Devices

SPDR S&P Health Equip

The influencer miracle drug exosome turns out to be a product with three no's! So-Young has removed "related medical beauty projects" from the shelves

Akso Health Group (AHG) shares surged 85.2% following a 75.6% revenue increase, reaching a new 52-week high. This growth raises questions about the company's sustainability amid past losses and cash concerns. Analysts suggest that while the revenue spike has attracted market attention, it does not resolve issues related to cash burn and reliance on new capital. Current fair value estimates for AHG stock hover around $0.25, indicating a complex investment narrative that requires careful consideration before making decisions.

Simplywall

Akso Health

Akso Health Group (AHG) Is Up 85.2% After 75.6% Revenue Surge And New 52-Week High - Has The Bull Case Changed?

MEDP

Medpace Holdings (MEDP) has experienced mixed stock performance, with a recent 4.3% decline over the past week but a 38.6% return over the last year. Analysts suggest the stock is undervalued by 21.8% based on a Discounted Cash Flow (DCF) analysis, estimating an intrinsic value of $575.79 per share. However, its P/E ratio of 28.34x is above the tailored fair ratio of 23.02x, indicating it may be overvalued. Investors are encouraged to consider their own narratives and forecasts when evaluating the stock's attractiveness.

Medpace

iShares Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

ALPS Medical Breakthrough

Is Medpace Holdings (MEDP) Still Appealing After Recent Volatility And Zelluna Partnership Expectations

Ausdal Financial Partners Inc. has acquired a new stake in Exact Sciences Corporation, purchasing 90,988 shares valued at approximately $4.98 million. Other institutional investors have also adjusted their positions in EXAS. Analysts have mixed opinions on the stock, with William Blair downgrading it to 'market perform' and Wells Fargo raising its price target to $105. Exact Sciences reported a loss of $0.21 EPS in its latest earnings, missing estimates, but revenue increased by 23.1% year-over-year. The stock is currently trading at $103.57 with a market cap of $19.77 billion.

Market Beat

Exact Sciences

Ausdal Financial Partners Inc. Buys New Position in Exact Sciences Corporation $EXAS

IBBQ

Charles River Laboratories (CRL) recently exceeded quarterly expectations and announced a US$1 billion share buyback while undergoing restructuring. Despite a 1.83% one-day share price increase, the stock has seen a 23.20% year-to-date gain. Analysts suggest CRL is undervalued at $155.46 compared to a fair value of $313.61, although a discounted cash flow model indicates it may be overvalued at this price. The contrasting views on CRL's valuation highlight the importance of assessing growth potential and cash flow sustainability in investment decisions.

Invesco Nasdaq Biotechnology ETF

Charles River Laboratorie

A Look At Charles River Laboratories (CRL) Valuation After Its Earnings Beat And New US$1b Buyback

OMDA

Omada Health, a digital healthcare platform, aims to improve patient outcomes between doctor visits. The company reported a 53% sales growth in 2025 and trades at just 3 times sales, indicating strong growth potential. Despite initial struggles post-IPO, Omada's market cap stands at $800 million, with promising data on member health improvements, particularly for those using GLP-1 medications. However, it was not included in a recent list of top stock recommendations by The Motley Fool, which suggests investors consider other options for potentially higher returns.

nasdaq

Omada Health

Could This $14 Stock Be Your Ticket to Millionaire Status?

DRIO

DarioHealth Corp. (NASDAQ:DRIO) experienced a 24.6% decrease in short interest in February, with 50,473 shares short as of February 27th, down from 66,964 shares on February 12th. The days-to-cover ratio is currently 6.2 days, with approximately 0.8% of shares short sold. Institutional investors have increased their stakes, with notable acquisitions by Kestra Advisory Services LLC and Geode Capital Management LLC. Analyst ratings vary, with one Buy, one Hold, and one Sell rating, and an average price target of $38.00. DarioHealth specializes in chronic disease management through a digital health platform.

DarioHealth

Short Interest in DarioHealth Corp. (NASDAQ:DRIO) Drops By 24.6%

Humana's share price has significantly declined, closing at $165.43, with a 37.5% drop year-to-date. Despite this, a Discounted Cash Flow analysis suggests it is undervalued by 82.9%, with an estimated intrinsic value of $965.79 per share. Additionally, its P/E ratio of 16.72x is below industry averages, indicating further undervaluation. Investors are reassessing Humana's valuation amidst broader healthcare market trends, with varying fair value estimates based on growth expectations and market conditions.

Humana

Is It Time To Reconsider Humana (HUM) After Its Steep Share Price Slide?

JYNT

Maxim Group analyst Anthony Vendetti has maintained a Hold rating on JYNT stock, citing balanced risk/reward amid operational transitions and macroeconomic pressures. Despite stronger-than-expected quarterly results and early benefits from a new marketing strategy, Vendetti notes that these factors do not indicate sustained growth acceleration. Ongoing challenges include refranchising uncertainties and gradual regional expansion. He has modestly reduced revenue and earnings projections, justifying the Hold stance. B. Riley Securities also maintains a Hold rating with a $9.00 price target.

JOINT

Balanced Risk/Reward Amid Operational Transition and Macroeconomic Headwinds Supports Hold Rating

TALK

Universal Health Services (NYSE:UHS) has announced its acquisition of Talkspace, a virtual behavioral health provider, for approximately US$835 million, expected to close in 2026. This move emphasizes UHS's focus on integrating digital behavioral health services into its existing offerings. Investors should monitor the integration of Talkspace's tools, reimbursement responses, and UHS's high debt levels. Currently, UHS shares are trading about 29% below analyst targets and are considered undervalued, trading 65% below fair value. The acquisition aims to enhance UHS's digital focus in the growing virtual care market.

TalkSpace

Universal Health Service-B

Universal Health Services Bets On Talkspace And Undervalued Digital Growth

Zacks Research has downgraded Pharming Group (NASDAQ:PHAR) from a "hold" to a "strong sell" rating. This follows mixed analyst opinions, with some firms maintaining buy ratings and price targets ranging from $37 to $41. Pharming's recent earnings report showed a revenue of $106.5 million, missing expectations, which may have contributed to the downgrade. The stock has a market cap of $1.02 billion and a PE ratio of 1,451.00, with a current price of $14.51, down 4.2%.

Pharming Group NV

iShares US Pharma

Pharming Group (NASDAQ:PHAR) Downgraded to Strong Sell Rating by Zacks Research

Sirios Capital Management L P increased its stake in Tenet Healthcare Corporation (NYSE:THC) by 100.9% in Q3, acquiring an additional 35,947 shares, bringing its total to 71,566 shares. This investment represents 1.9% of Sirios' portfolio. Other institutional investors also adjusted their stakes in THC. Tenet Healthcare's stock opened at $227.79, with a market cap of $19.81 billion and a P/E ratio of 14.71. The company reported $4.70 EPS for the last quarter, exceeding estimates, and has set FY 2026 guidance at 16.190-18.470 EPS.

Tenet Healthcare

Sirios Capital Management L P Buys 35,947 Shares of Tenet Healthcare Corporation $THC

Charles River Laboratories International, Inc. (NYSE:CRL) has received an average rating of "Moderate Buy" from sixteen brokerages. One analyst rated it as a sell, five as hold, and ten as buy. The average target price is $203.57. Recent upgrades include Bank of America raising its target to $225 and Citigroup to $265. The stock opened at $155.61, with a market cap of $7.66 billion. The company reported $2.39 EPS, beating estimates, but revenue was down 0.8% year-over-year. FY 2026 guidance is set at 10.700-11.200 EPS.

Direxion S&P Biotech Bear 3X

Charles River Laboratories International, Inc. (NYSE:CRL) Given Average Rating of "Moderate Buy" by Brokerages

HNGE

Hinge Health's stock recently closed at $45.00, reflecting a 16.1% gain over 30 days but a decline of 2.5% in the last week. A Discounted Cash Flow analysis suggests the stock is undervalued by 71%, with an intrinsic value of $155.02 per share. However, its Price-to-Sales ratio of 6.03x is above industry averages, indicating it may be overvalued. Analysts provide varying fair value estimates, ranging from $43.40 to $72.00, prompting investors to reassess its market position and potential risks.

Hinge Health

Is It Time To Reassess Hinge Health (HNGE) After Its Recent Share Price Rebound?

iShares US Healthcare Providers(IHF.US)

Oneview Healthcare Raises A$19m in Upsized Placement and Launches SPP to Fund AI and Growth

The influencer miracle drug exosome turns out to be a product with three no's! So-Young has removed "related medical beauty projects" from the shelves

Akso Health Group (AHG) Is Up 85.2% After 75.6% Revenue Surge And New 52-Week High - Has The Bull Case Changed?

Is Medpace Holdings (MEDP) Still Appealing After Recent Volatility And Zelluna Partnership Expectations

Ausdal Financial Partners Inc. Buys New Position in Exact Sciences Corporation $EXAS